Market News & Trends
9/25/2012
BD Introduces Shortest, Thinnest Pen Needle Studies suggest that as many as one-fifth to one-third of people with diabetes are hesitant or unwilling to…
BD Introduces Shortest, Thinnest Pen Needle
Studies suggest that as many as one-fifth to one-third of people with diabetes are hesitant or unwilling to give themselves insulin injections for reasons that…
Catalent Completes $350-Million Offering
Catalent Pharma Solutions, Inc. recently announced the successful completion of its $350-million offering of 7.875% Senior Notes due 2018, issued at par. Catalent has used…
JHP Pharmaceuticals to Produce Lyophilized Biologic
JHP Pharmaceuticals recently announced it has entered into an agreement with an undisclosed pharmaceutical company to produce supplies of a lyophilized biologic for international, late-phase…
9/19/2012
PharmaTelevision Spotlights Aptalis' Year in Review FDA approvals, revenue gain, and organic business growth are just a few of the topics that John Fraher, President,…
Catalent & CTC Bio to Help Korean Pharma Enter New Markets
Catalent Pharma Solutions and CTC Bio have entered into a collaboration to provide optimal solutions to South Korean pharmaceutical companies seeking to commercialize solid oral…
Ei Gains Exclusive World-Wide License
Metro Charlotte-based Ei has signed agreements with European-based professors and technologists for the exclusive worldwide license of a novel class of sphingolipids. Sphingolipids are found…
Life Technologies to Partner With Bristol-Myers Squibb
Life Technologies Corporation recently announced the company has entered into a Master Development Agreement with Bristol-Myers Squibb Company for current and future companion diagnostics projects.…
PharmaTelevision Spotlights Aptalis' Year in Review
FDA approvals, revenue gain, and organic business growth are just a few of the topics that John Fraher, President, Aptalis Pharma, addresses during an on-air…
Synergy Files IND for GI Diseases
Synergy Pharmaceuticals, Inc. recently announced that an Investigational New Drug (IND) application was submitted on September 7, 2012, for clinical evaluation of SP-333 to treat…
Xcelience Opens New Development Facility
Xcelience LLC recently announced the grand opening of a new 24,000-sq-ft facility, located south of the Tampa airport at 4901 Grace Street. The building will…
West Announces Self-Injection Technology Agreement
West recently announced an agreement with Janssen Biotech, Inc. to collaborate on the development and manufacturing of an innovative self-injection product. The technology, developed by…
9/12/2012
Cobra Biologics & Algeta Sign Monoclonal Antibody Agreement Cobra Biologics Ltd and Algeta ASA recently announced a new contract manufacturing partnership for Algeta's fourth Targeted…
Cobra Biologics & Algeta Sign Monoclonal Antibody Agreement
Cobra Biologics Ltd and Algeta ASA recently announced a new contract manufacturing partnership for Algeta's fourth Targeted Thorium Conjugate (TTC) program. The program will focus…
Growth Predicted for the European Vaccines Market
As vaccine manufacturers increasingly tend to leverage on novel technologies, and potential late-stage vaccine candidates progress the pipeline and reach the commercialization stage, the European…
InSite Vision Introduces DuraSite 2
InSite Vision Incorporated recently introduced DuraSite 2, its next-generation enhanced drug delivery system that provides a broad platform for developing superior ophthalmic therapeutics. DuraSite 2…
Quotient & Pulmatrix Announce Completion of Innovative Program
Quotient Clinical and Pulmatrix recently announced the completion of an early clinical program to achieve proof-of-concept data in COPD patients for PUR118, Pulmatrix's lead iCALM…
Third Critically Ill Patient Successfully Treated With PLX Cells Under Compassionate Use
Pluristem Therapeutics, Inc. recently announced the company's Placental eXpanded (PLX) cells were successfully administered to a third patient in Hadassah Medical Center; thus, a series…
9/5/2012
Genmab Signs Potential Billion Dollar Agreement Genmab recently announced a global license and development agreement for daratumumab (HuMax-CD38), a human CD38 monoclonal antibody with Janssen…
Charles River Buys Company for $17 Million
Charles River Laboratories International, Inc. recently announced it has acquired Accugenix, Inc., the premier global provider of cGMP-compliant contract microbial identification testing, for approximately $17…
